专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130324465A1 VEGF ANTAGONIST COMPOSITIONS AND USES THEREOF 有权
标题翻译： VEGF拮抗剂组合物及其用途
公开(公告)号：US20130324465A1
公开(公告)日：2013-12-05
申请号：US13814182
申请日：2011-08-05
申请人： James Stefano , Clark Pan , Huawei Qiu , Michael O'Callaghan , Gloria Matthews
发明人： James Stefano , Clark Pan , Huawei Qiu , Michael O'Callaghan , Gloria Matthews
IPC分类号： C07K14/71 , C12N9/12
CPC分类号： C12N9/12 , C07K14/71 , C12Y207/10001
摘要： The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
摘要翻译：本发明提供用于治疗与血管内皮生长因子（VEGF）相关的疾病或病症的组合物和方法。具体地，本发明涉及提供VEGF拮抗作用的低聚VEGF结合结构域，从而治疗与之相关的疾病。

2. 发明授权

US07507714B2 Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use 有权
标题翻译：垂体腺苷酸环化酶活化肽（PACAP）受体3（R3）激动剂及其药理学用途
公开(公告)号：US07507714B2
公开(公告)日：2009-03-24
申请号：US10892981
申请日：2004-07-15
申请人： Clark Pan , Manami Tsutsumi , Armen B. Shanafelt
发明人： Clark Pan , Manami Tsutsumi , Armen B. Shanafelt
IPC分类号： A61K38/16 , C07K14/00
CPC分类号： C07K14/575 , A61K38/00 , A61K48/00
摘要： This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
摘要翻译：本发明提供了新的肽，其在体内起作用以以葡萄糖依赖的方式刺激胰腺β细胞的胰岛素释放。这些胰岛素促分泌肽显示能够在体外和体内刺激大鼠胰岛细胞中的胰岛素释放。本发明的肽为具有降低的内源性胰岛素分泌的患者特别是2型糖尿病患者提供了新的疗法。特别地，本发明是选自VIP / PACAP相关多肽的特定组的多肽或其功能等同物。本发明还涉及一种治疗哺乳动物代谢疾病的方法，包括向所述哺乳动物施用治疗有效量的胰岛素促分泌肽。还公开了制备重组体和合成肽的方法。

3. 发明授权

US07494978B2 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use 失效
标题翻译：作为GLP-1受体激动剂和胰高血糖素受体拮抗剂的肽及其药理学用途
公开(公告)号：US07494978B2
公开(公告)日：2009-02-24
申请号：US11213087
申请日：2005-08-26
申请人： Clark Pan , James Whelan , Kevin B. Clairmont
发明人： Clark Pan , James Whelan , Kevin B. Clairmont
IPC分类号： A61K38/00 , A61K38/28 , C07K2/00
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
摘要翻译：本发明提供了作为GLP-1受体的激动剂和胰高血糖素受体拮抗剂的作用的多肽。这样的多肽可用于治疗2型糖尿病或其他代谢紊乱的个体。

4. 发明申请

US20090010874A1 MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS 失效
标题翻译：修饰的IL-4 MUTEIN受体拮抗剂
公开(公告)号：US20090010874A1
公开(公告)日：2009-01-08
申请号：US11940217
申请日：2007-11-14
申请人： Clark Pan , Steve Roczniak , Jeffrey Michael Greve , Stephanie L. Yung , Malinda Longphre , Teresa Mo-Fun Wong , Adrian Tomkinson
发明人： Clark Pan , Steve Roczniak , Jeffrey Michael Greve , Stephanie L. Yung , Malinda Longphre , Teresa Mo-Fun Wong , Adrian Tomkinson
IPC分类号： C07K14/54 , A61K38/20
CPC分类号： C07K14/5406 , A61K38/00 , C07K14/7155
摘要： This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
摘要翻译：本发明涉及包含与聚乙二醇偶联的IL-4突变蛋白受体拮抗剂的经修饰的IL-4突变蛋白受体拮抗剂。还提供了用于治疗目的的相关制剂和剂量及其施用方法。这些修饰的IL-4突变蛋白受体拮抗剂，组合物和方法通过抑制IL-4和IL-13介导的气道高反应性和嗜酸性粒细胞增多为患有呼吸系统疾病如哮喘的个体提供治疗选择。更具体地，这些拮抗剂由于更大的血浆半衰期而对未改性的IL-4RA具有增加的作用持续时间。

5. 发明申请

US20080261863A1 Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use 审中-公开
标题翻译：血管活性肽（Vip）/垂体腺苷酸环化酶活化肽（Pacap）受体2（Vpac2）激动剂和使用方法的PEG化
公开(公告)号：US20080261863A1
公开(公告)日：2008-10-23
申请号：US11632465
申请日：2005-06-10
申请人： James Whelan , Clark Pan
发明人： James Whelan , Clark Pan
IPC分类号： A61K38/28 , C07K14/00 , C07H21/00 , C12N15/63 , C12N5/00 , A61P3/10 , C12P21/00 , C07K1/107 , A61K38/16
CPC分类号： C07K14/57563 , A61K38/00 , A61K45/06 , A61K47/60
摘要： This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods are useful in providing a treatment option for those individuals afflicted with a metabolic disorder such as diabetes, impaired glucose tolerance, metabolic syndrome, or prediabetic states, by inducing glucose-dependent insulin secretion in the absence of the therapeutically limiting side effect of reducing or lowering blood pressure.
摘要翻译：本发明涉及包含与聚乙二醇聚合物连接的VPAC2激动剂的修饰的血管活性肠肽（VIP）/垂体腺苷酸环化酶活化肽（PACAP）受体2（VPAC2）激动剂（VPAC2激动剂）以及相关制剂，剂量和给药方法用于治疗目的。这些VPAC2激动剂，组合物和方法可用于通过在不存在葡萄糖的情况下诱导葡萄糖依赖性胰岛素分泌为那些患有代谢性疾病例如糖尿病，葡萄糖耐量降低，代谢综合征或前驱糖尿病状态的患者提供治疗选择治疗上限制降低或降低血压的副作用。

6. 发明授权

US07404957B2 Modified IL-4 mutein receptor antagonists 失效
标题翻译：修饰的IL-4突变蛋白受体拮抗剂
公开(公告)号：US07404957B2
公开(公告)日：2008-07-29
申请号：US10820559
申请日：2004-04-08
申请人： Clark Pan , Steve Roczniak , Jeffrey Michael Greve , Stephanie L. Yung , Malinda Longphre , Teresa Mo-fun Wong , Adrian Tomkinson
发明人： Clark Pan , Steve Roczniak , Jeffrey Michael Greve , Stephanie L. Yung , Malinda Longphre , Teresa Mo-fun Wong , Adrian Tomkinson
IPC分类号： A61K38/20 , A61K38/00 , C12P21/06 , C07K14/47
CPC分类号： A61K38/1709 , C07K14/5406 , C07K14/7155
摘要： This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
摘要翻译：本发明涉及包含与聚乙二醇偶联的IL-4突变蛋白受体拮抗剂的经修饰的IL-4突变蛋白受体拮抗剂。还提供了用于治疗目的的相关制剂和剂量及其施用方法。这些修饰的IL-4突变蛋白受体拮抗剂，组合物和方法通过抑制IL-4和IL-13介导的气道高反应性和嗜酸性粒细胞增多为患有呼吸系统疾病如哮喘的个体提供治疗选择。更具体地，这些拮抗剂由于更大的血浆半衰期而对未改性的IL-4RA具有增加的作用持续时间。

7. 发明申请

US20070160614A1 Human TIMP-1 antibodies 失效
标题翻译：人TIMP-1抗体
公开(公告)号：US20070160614A1
公开(公告)日：2007-07-12
申请号：US11504527
申请日：2006-08-14
申请人： Clark Pan , Andreas Knorr , Michael Schauer , Claudia Hirth-Dietrich , Sabine Kraft , Barbara Krebs
发明人： Clark Pan , Andreas Knorr , Michael Schauer , Claudia Hirth-Dietrich , Sabine Kraft , Barbara Krebs
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/40
CPC分类号： C07K16/38 , A61K2039/505 , C07K16/005 , C07K16/18 , C07K16/40 , C07K2317/21 , C07K2317/55 , C07K2317/76
摘要： Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.
摘要翻译：结合TIMP-1的人抗体可用作诊断和治疗TIMP-1升高的疾病的试剂，如肝纤维化，酒精性肝病，心脏纤维化，急性冠状动脉综合征，狼疮性肾炎，肾小球硬化性肾病，良性前列腺肥大，结肠癌，肺癌和特发性肺纤维化。

8. 发明申请

US20060003935A1 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use 审中-公开
公开(公告)号：US20060003935A1
公开(公告)日：2006-01-05
申请号：US11213024
申请日：2005-08-26
申请人： Clark Pan , James Whelan , Kevin Clairmont
发明人： Clark Pan , James Whelan , Kevin Clairmont
IPC分类号： A61K38/17
CPC分类号： C07K14/605 , A61K38/1709 , A61K38/26
摘要： The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.

9. 发明申请

US20060003418A1 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use 审中-公开
公开(公告)号：US20060003418A1
公开(公告)日：2006-01-05
申请号：US11213083
申请日：2005-08-26
申请人： Clark Pan , James Whelan , Kevin Clairmont
发明人： Clark Pan , James Whelan , Kevin Clairmont
IPC分类号： A61K38/17 , A61K48/00 , C07K14/47 , C07K16/18
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.

10. 发明授权

US09441029B2 VEGF antagonist compositions and uses thereof 有权
标题翻译： VEGF拮抗剂组合物及其用途
公开(公告)号：US09441029B2
公开(公告)日：2016-09-13
申请号：US13814182
申请日：2011-08-05
申请人： James Stefano , Clark Pan , Huawei Qiu , Michael O'Callaghan , Gloria Matthews
发明人： James Stefano , Clark Pan , Huawei Qiu , Michael O'Callaghan , Gloria Matthews
IPC分类号： A61K38/00 , C07K14/435 , C07K14/71 , C12N9/12
CPC分类号： C12N9/12 , C07K14/71 , C12Y207/10001
摘要： The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
摘要翻译：本发明提供用于治疗与血管内皮生长因子（VEGF）相关的疾病或病症的组合物和方法。具体地，本发明涉及提供VEGF拮抗作用的低聚VEGF结合结构域，从而治疗与之相关的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式